Liver Transplant Rejection - Pipeline Review, H1 2018

  • ID: 4482751
  • Drug Pipelines
  • 72 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Dompe Farmaceutici SpA
  • Novartis AG
  • RedHill Biopharma Ltd
  • MORE
Liver Transplant Rejection - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Liver Transplant Rejection - Pipeline Review, H1 2018, provides an overview of the Liver Transplant Rejection (Immunology) pipeline landscape.

Liver transplantation is the conventional therapy used in various liver diseases. Liver has the unique ability to regenerate or grow, unlike any other organ in the body. Liver transplant replaces an injured or diseased liver with a healthy one. An entire liver or just a section may be transplanted. Following a transplant, the immune system may consider the transplanted liver as foreign and may work against it. Patients may hence develop complications and ultimately reject the new organ. Therefore, immunosuppressive drugs are administered simultaneously. These immunosuppressive drugs prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Liver Transplant Rejection - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Liver Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Liver Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 4, 3 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 1, 2, 1 and 1 molecules, respectively.

Liver Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Transplant Rejection (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Liver Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Liver Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Liver Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Liver Transplant Rejection (Immunology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Liver Transplant Rejection (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Liver Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Astellas Pharma Inc
  • Dompe Farmaceutici SpA
  • Novartis AG
  • RedHill Biopharma Ltd
  • MORE
Introduction

Report Coverage

Liver Transplant Rejection - Overview

Liver Transplant Rejection - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Liver Transplant Rejection - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Liver Transplant Rejection - Companies Involved in Therapeutics Development

Astellas Pharma Inc

Dompe Farmaceutici SpA

Novartis AG

RedHill Biopharma Ltd

Veloxis Pharmaceuticals A/S

Liver Transplant Rejection - Drug Profiles

ABC-294640 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Liver Transplant Rejection - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Liver Transplantation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Liver Transplantation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Transplant Rejection and Inflammatory Bowel Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CFZ-533 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emricasan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FX-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for High-Grade Glioma and Liver Transplantation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-204 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

reparixin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tacrolimus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tacrolimus ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TR-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Triplex - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Liver Transplant Rejection - Dormant Projects

Liver Transplant Rejection - Discontinued Products

Liver Transplant Rejection - Product Development Milestones

Featured News & Press Releases

Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting

May 12, 2014: Conatus Pharmaceuticals Initiates Phase 2b Trial Targeting Fibrosis in Liver Transplant Recipients

Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting

Dec 04, 2009: Hikma signs new agreement for Advagraf with Astellas

Jun 23, 2008: Astellas submit an sNDA for the immunosuppressant Prograf for Ulcerative Colitis in Japan

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Liver Transplant Rejection, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Liver Transplant Rejection - Pipeline by Astellas Pharma Inc, H1 2018

Liver Transplant Rejection - Pipeline by Dompe Farmaceutici SpA, H1 2018

Liver Transplant Rejection - Pipeline by Novartis AG, H1 2018

Liver Transplant Rejection - Pipeline by RedHill Biopharma Ltd, H1 2018

Liver Transplant Rejection - Pipeline by Veloxis Pharmaceuticals A/S, H1 2018

Liver Transplant Rejection - Dormant Projects, H1 2018

Liver Transplant Rejection - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Liver Transplant Rejection, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Astellas Pharma Inc
  • Dompe Farmaceutici SpA
  • Novartis AG
  • RedHill Biopharma Ltd
  • Veloxis Pharmaceuticals A/S
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll